{
  "pmcid": "7528522",
  "sha256": "9550e6167a44c104f75b01930bbd0efb01c773377cac5f3501a9599131ea8f60",
  "timestamp_utc": "2025-11-10T00:06:45.362551+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 10.302172939068104,
    "reading_ease": 41.9065927419355,
    "word_count": 279
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Acellular Dermal Matrix in Implant-Based Breast Reconstruction"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomly assigned (1:1)"
      },
      "Participants": {
        "score": 2,
        "evidence": "women with breast cancer planned for mastectomy with immediate IBBR"
      },
      "Intervention": {
        "score": 2,
        "evidence": "IBBR with or without ADM"
      },
      "Objective": {
        "score": 1,
        "evidence": "assessed whether implant-based breast reconstruction (IBBR) with acellular dermal matrix (ADM) enhances health-related quality of life (HRQoL) and patient-reported cosmetic outcomes compared to conventional IBBR without ADM"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the number of reoperations within 6 months"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed until baseline questionnaires were completed"
      },
      "Blinding": {
        "score": 3,
        "evidence": "The study was open-label"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Between April 2014 and May 2017, 135 women were randomised: 65 to the ADM group and 70 to the control group"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis included 64 in the ADM group and 65 in the control group"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "cosmetic outcome (mean difference 8.66, 95% CI 0.46 to 16.86; p = 0.041)"
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events requiring reoperation were more frequent in the ADM group"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT02061527"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified"
      }
    },
    "total_score": 23,
    "max_score": 25
  }
}